Psychedelic Therapy for PTSD
Post-traumatic stress disorder (PTSD) is the primary indication for MDMA-assisted therapy, which showed unprecedented efficacy in Phase 3 trials — with 67% of participants no longer meeting PTSD criteria after treatment. Following an FDA rejection in August 2024, sponsors are preparing resubmission with additional safety data, and multiple other compounds are entering the PTSD pipeline.
Psilocybin and ayahuasca are also being studied for PTSD, particularly for veterans and first responders. The combination of a therapeutic session structure with the substance's ability to reduce fear responses and facilitate emotional processing makes PTSD one of the most compelling targets in psychedelic medicine.
Clinical Trials
17 trials currently recruiting
A Study of Psilocybin for PTSD
Johns Hopkins University
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder
Ohio State University
MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD
Dr. Leslie Morland
Group MDMA-therapy for Veterans With PTSD
Portland VA Research Foundation, Inc
Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD
Albany Research Institute, Inc.
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMPASS Pathways
Companies & Research
Organizations with active ptsd research programs